Skip to main content
Top
Published in: Journal of Neuro-Oncology 2/2014

01-01-2014 | Clinical Study

Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center

Authors: Francisco Helder Cavalcante Felix, Orlandira Leite de Araujo, Karine Martins da Trindade, Nadia Mendonça Trompieri, Juvenia Bezerra Fontenele

Published in: Journal of Neuro-Oncology | Issue 2/2014

Login to get access

Abstract

Diffuse intrinsic pontine glioma is a pediatric oncologic disease with dismal prognosis and no effective treatment. Since 2007, our patients have been using valproic acid as prophylactic anticonvulsant. We have undertaken a retrospective study in order to evaluate the influence of valproate in the outcomes of children with this disease in our center. Patients were treated with weekly carboplatin and vincristine and received conformal radiotherapy, either concurrent or sequential. Event-free survival and overall survival of patients not treated with valproic acid were 6.5 and 7.8 months. Accelerated failure time model (a parametric multivariate regression test for time-to-failure data) showed a statistically significant superiority of the median event-free survival of treated patients (6.5 vs. 9.5 months in treated patients; HR 0.54–95 % CI 0.33–0.87; p < 0.05) and also of overall survival (7.8 vs. 13.4 months in treated patients; HR 0.60–95 % CI 0.37–0.98; p = 0.05).
Appendix
Available only for authorised users
Literature
1.
go back to reference Jenkin RD, Boesel C, Ertel I et al (1987) Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Children’s Cancer Study Group. J Neurosurg 66(2):227–233PubMedCrossRef Jenkin RD, Boesel C, Ertel I et al (1987) Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Children’s Cancer Study Group. J Neurosurg 66(2):227–233PubMedCrossRef
2.
go back to reference Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248PubMedCrossRef Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248PubMedCrossRef
3.
go back to reference Wells EM, Gaillard WD, Packer RJ (2012) Pediatric brain tumors and epilepsy. Semin Pediatr Neurol 19(1):3–8PubMedCrossRef Wells EM, Gaillard WD, Packer RJ (2012) Pediatric brain tumors and epilepsy. Semin Pediatr Neurol 19(1):3–8PubMedCrossRef
4.
go back to reference Tremont-Lukats I, Ratilal B, Armstrong T et al (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 16(2):CD004424 Tremont-Lukats I, Ratilal B, Armstrong T et al (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 16(2):CD004424
5.
go back to reference Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13(9):e375–e382PubMedCrossRef Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13(9):e375–e382PubMedCrossRef
6.
go back to reference Kawasaki M, Hernández-Fustes OJ, Machado S, Aguiar LR, Mattar F, Panfilio CB, Hernández-Cossio O (1999) Epilepsia y tumor cerebral. Rev Neurol 28(11):1047–1049PubMed Kawasaki M, Hernández-Fustes OJ, Machado S, Aguiar LR, Mattar F, Panfilio CB, Hernández-Cossio O (1999) Epilepsia y tumor cerebral. Rev Neurol 28(11):1047–1049PubMed
7.
go back to reference Felix FH, de Araujo OL, da Trindade KM et al (2013) Survival of children with malignant brain tumors receiving valproate: a retrospective study. Childs Nerv Syst 29(2):195–197PubMedCrossRef Felix FH, de Araujo OL, da Trindade KM et al (2013) Survival of children with malignant brain tumors receiving valproate: a retrospective study. Childs Nerv Syst 29(2):195–197PubMedCrossRef
8.
go back to reference Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556–570PubMedCrossRef Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556–570PubMedCrossRef
9.
go back to reference Packer RJ, Lange B, Ater J et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11(5):850–856PubMed Packer RJ, Lange B, Ater J et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11(5):850–856PubMed
10.
go back to reference Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280PubMed
11.
go back to reference Chassot A, Canale S, Varlet P et al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 106(2):399–407PubMedCrossRef Chassot A, Canale S, Varlet P et al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 106(2):399–407PubMedCrossRef
12.
go back to reference Brandes AA, Franceschi E, Gorlia T et al (2012) European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 48(6):896–903PubMedCrossRef Brandes AA, Franceschi E, Gorlia T et al (2012) European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 48(6):896–903PubMedCrossRef
13.
go back to reference Hargrave D, Chuang N, Bouffet E (2008) Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 86(3):313–319PubMedCrossRef Hargrave D, Chuang N, Bouffet E (2008) Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 86(3):313–319PubMedCrossRef
14.
go back to reference Masoudi A, Elopre M, Amini E et al (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C):2437–2442PubMed Masoudi A, Elopre M, Amini E et al (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C):2437–2442PubMed
15.
go back to reference Oberndorfer S, Piribauer M, Marosi C et al (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol 72:255–260CrossRef Oberndorfer S, Piribauer M, Marosi C et al (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol 72:255–260CrossRef
16.
go back to reference Wolff J, Kramm C, Kortmann R et al (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90(3):309–314PubMedCrossRef Wolff J, Kramm C, Kortmann R et al (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90(3):309–314PubMedCrossRef
17.
go back to reference Weller M, Gorlia T, Cairncross JG et al (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRef Weller M, Gorlia T, Cairncross JG et al (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164PubMedCrossRef
19.
go back to reference Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509PubMedCrossRef Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509PubMedCrossRef
20.
go back to reference Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C et al (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34(3):206–222PubMedCrossRef Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C et al (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34(3):206–222PubMedCrossRef
21.
go back to reference Michaelis M, Michaelis UR, Fleming I et al (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65(3):520–527PubMedCrossRef Michaelis M, Michaelis UR, Fleming I et al (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65(3):520–527PubMedCrossRef
22.
go back to reference Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. J Neurooncol 109(1):23–33PubMedCrossRef Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. J Neurooncol 109(1):23–33PubMedCrossRef
23.
go back to reference Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 107(1):61–67PubMedCrossRef Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 107(1):61–67PubMedCrossRef
24.
go back to reference Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29(30):3999–4006PubMedCrossRef Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29(30):3999–4006PubMedCrossRef
25.
go back to reference Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J (2012) Baker SJ; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253PubMedCentralPubMedCrossRef Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J (2012) Baker SJ; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253PubMedCentralPubMedCrossRef
26.
go back to reference Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM (2013) A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a children’s oncology group phase 1 consortium study. Pediatr Blood Cancer 60(9):1452–1457PubMedCrossRef Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM (2013) A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a children’s oncology group phase 1 consortium study. Pediatr Blood Cancer 60(9):1452–1457PubMedCrossRef
27.
go back to reference Su JM, Li XN, Thompson P et al (2011) Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children’s oncology group report. Clin Cancer Res 17(3):589–597PubMedCentralPubMedCrossRef Su JM, Li XN, Thompson P et al (2011) Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children’s oncology group report. Clin Cancer Res 17(3):589–597PubMedCentralPubMedCrossRef
28.
go back to reference Friedman HS, Krischer JP, Burger P et al (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10(2):249–256PubMed Friedman HS, Krischer JP, Burger P et al (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10(2):249–256PubMed
29.
go back to reference Mabeta P, Pepper MS (2009) A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12(1):81–90PubMedCrossRef Mabeta P, Pepper MS (2009) A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12(1):81–90PubMedCrossRef
Metadata
Title
Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center
Authors
Francisco Helder Cavalcante Felix
Orlandira Leite de Araujo
Karine Martins da Trindade
Nadia Mendonça Trompieri
Juvenia Bezerra Fontenele
Publication date
01-01-2014
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1280-6

Other articles of this Issue 2/2014

Journal of Neuro-Oncology 2/2014 Go to the issue